From Probability...

Conceptual image representing dosing variability associated with splitting desmopressin tablets

to Precision.

The first and only FDA-approved oral desmopressin solution designed for precision in oral dosing for central diabetes insipidus (CDI)1*

Conceptual image representing dosing variability associated with splitting desmopressin tablets

Limitations of Use: DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus.1

*Desmopressin is also available in nasal and injectable dosage forms.

Living with CDI, also known as arginine vasopressin deficiency (AVP-D), can be challenging.2,3 Alternative formulations have important clinical limitations:

Splitting tablets to individualize dosing may lead to inconsistent, inaccurate doses4,5

Nasal sprays may deliver inconsistent doses if nasal congestion or inflammation is present6

Injections often require office visits, and may be associated with discomfort, needle fear, and injection site reactions7-10

For patients of all ages with CDI, DESMODA is designed to allow:

Precision

Helps deliver accurate, reproducible dosing every time1

Flexibility

Supports individualized dose adjustment using a precisely measured liquid formulation1

Consistency

Helps support a measured dose designed to be repeatable1

Control

Helps avoid the oral dosing variability associated with splitting tablets1,4,5

Conceptual image representing dosing variability associated with splitting desmopressin tablets

Learn more about DESMODA for CDI patients of all ages

Thanks for connecting with us.

References: 1. DESMODA. Package Insert. Eton Pharmaceuticals; 2026. 2. Arima H, Cheetham T, Christ-Crain M, et al. J Clin Endocrinol Metab. 2022;108(1):1-3. 3. Teare H, Argente J, Dattani M, et al. Orphanet J Rare Dis. 2022;17(1):58. 4. Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. J Adv Nurs. 2011;67(1):26-32. 5. Saran AK, Holden NA, Garrison SR. BJGP Open. 2022;6(3):BJGPO.2022.0001. 6. Chin X, Teo SW, Lim ST, Ng YH, Han HC, Yap F. Eur J Clin Pharmacol. 2022;78(6):907-917. 7. Atila C, Refardt J, Christ-Crain M. Nat Rev Endocrinol. 2024;20(8):487-500. 8. Zhi L, Liu D, Shameem M. AAPS Open. 2025;11:5. 9. McLenon J, Rogers MAM. J Adv Nurs. 2019;75(1):30-42. 10. Centers for Disease Control and Prevention. CDC. August 9, 2024. Accessed February 2, 2026. https://www.cdc.gov/vaccines-children/before-during-after-shots/index.htm

USE AND IMPORTANT SAFETY INFORMATION
USE AND IMPORTANT SAFETY INFORMATION

You are now navigating to the healthcare provider site

Are you a healthcare provider?

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave? 

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave? 

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave? 

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave? 

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave? 

YOU ARE NOW LEAVING DESMODA.com

Are you sure you want to leave?